(2S)-1-[(TERT-BUTOXY)CARBONYL]-2-PROPYLPYRROLIDINE-2-CARBOXYLIC ACID, 95%, 1g

Plan PLPHi 10x/0,25 contraste de fase Objetivo corregido al infinito IOS

(-)-Huperzine A>98.0%(HPLC)10mg

VK3-OCH3>98.0%(HPLC)50mg

Methyl 3,3,3-trifluoro-2,2-dimethylpropanoate, 95.0%, 1g

Cloruro de indio(III), mínimo 99,9 %, pa, 50 g, envase de plástico.

Sulfato de magnesio, mínimo 98%, pa, anhidro, granulado, 1 kg, envase de vidrio

Estándar de densidad, ROTI®Calipure, 0,7033 g/ml (20 °C), 100 ml, envase de vidrio

(6aR,8S,10aS)-10a-(4-chlorophenylsulfonyl)-1,4-difluoro-6a,7,8,9,10,10a-hexahydro-6H-benzo[c]chromen-8-ol, 97%, 100mg

Methyl 7-bromo-1-benzofuran-5-carboxylate, 98%, 1g

7-Bromobenzothiophene, 95.0%, 100g

(E)-4-CHLORO-2-(3-(4-PENTYLPHENYL)ACRYLAMIDO)BENZOIC ACID, 95.0%, 10mg

di-tert-Butyl ((2S,2'S)-(thiocarbonylbis(azanediyl))bis(propane-1,2-diyl))dicarbamate, 97%, 1g